PortalPublikationenEGF61 polymorphism predicts complete pathologic response to ...

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

Standard

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. / Hu-Lieskovan, Siwen; Vallbohmer, Daniel; Zhang, Wu; Yang, Dongyun; Pohl, Alexander; Labonte, Melissa J; Grimminger, Peter P; Hölscher, Arnulf H; Semrau, Robert; Arnold, Dirk; Dellas, Kathrin; Debucquoy, Annelies; Haustermans, Karin; Machiels, Jean-Pascal H; Sempoux, Christine; Rödel, Claus; Bracko, Matej; Velenik, Vaneja; Lenz, Heinz-Josef.

in: CLIN CANCER RES, Jahrgang 17, Nr. 15, 15, 2011, S. 5161-5169.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hu-Lieskovan, S, Vallbohmer, D, Zhang, W, Yang, D, Pohl, A, Labonte, MJ, Grimminger, PP, Hölscher, AH, Semrau, R, Arnold, D, Dellas, K, Debucquoy, A, Haustermans, K, Machiels, J-PH, Sempoux, C, Rödel, C, Bracko, M, Velenik, V & Lenz, H-J 2011, 'EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.', CLIN CANCER RES, Jg. 17, Nr. 15, 15, S. 5161-5169. <http://www.ncbi.nlm.nih.gov/pubmed/21673069?dopt=Citation>

APA

Hu-Lieskovan, S., Vallbohmer, D., Zhang, W., Yang, D., Pohl, A., Labonte, M. J., Grimminger, P. P., Hölscher, A. H., Semrau, R., Arnold, D., Dellas, K., Debucquoy, A., Haustermans, K., Machiels, J-P. H., Sempoux, C., Rödel, C., Bracko, M., Velenik, V., & Lenz, H-J. (2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. CLIN CANCER RES, 17(15), 5161-5169. [15]. http://www.ncbi.nlm.nih.gov/pubmed/21673069?dopt=Citation

Vancouver

Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ et al. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. CLIN CANCER RES. 2011;17(15):5161-5169. 15.

Bibtex

@article{0b2917c62bc643cfa352513714757b13,
title = "EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.",
abstract = "Cetuximab has shown significant clinical activity in metastatic colon cancer. However, cetuximab-containing neoadjuvant chemoradiation has not been shown to improve tumor response in locally advanced rectal cancer patients in recent phase I/II trials. We evaluated functional germline polymorphisms of genes involved in epidermal growth factor receptor pathway, angiogenesis, antibody-dependent cell-mediated cytotoxicity, DNA repair, and drug metabolism, for their potential role as molecular predictors for clinical outcome in locally advanced rectal cancer patients treated with preoperative cetuximab-based chemoradiation.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Combined Modality Therapy, Mutation, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Proto-Oncogene Proteins/*genetics, ras Proteins/*genetics, Antibodies, Monoclonal/*administration & dosage, Epidermal Growth Factor/*genetics, *Polymorphism, Genetic, Rectal Neoplasms/*drug therapy/*genetics/radiotherapy, Adult, Humans, Male, Aged, Female, Middle Aged, Aged, 80 and over, Combined Modality Therapy, Mutation, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Proto-Oncogene Proteins/*genetics, ras Proteins/*genetics, Antibodies, Monoclonal/*administration & dosage, Epidermal Growth Factor/*genetics, *Polymorphism, Genetic, Rectal Neoplasms/*drug therapy/*genetics/radiotherapy",
author = "Siwen Hu-Lieskovan and Daniel Vallbohmer and Wu Zhang and Dongyun Yang and Alexander Pohl and Labonte, {Melissa J} and Grimminger, {Peter P} and H{\"o}lscher, {Arnulf H} and Robert Semrau and Dirk Arnold and Kathrin Dellas and Annelies Debucquoy and Karin Haustermans and Machiels, {Jean-Pascal H} and Christine Sempoux and Claus R{\"o}del and Matej Bracko and Vaneja Velenik and Heinz-Josef Lenz",
year = "2011",
language = "English",
volume = "17",
pages = "5161--5169",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

RIS

TY - JOUR

T1 - EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

AU - Hu-Lieskovan, Siwen

AU - Vallbohmer, Daniel

AU - Zhang, Wu

AU - Yang, Dongyun

AU - Pohl, Alexander

AU - Labonte, Melissa J

AU - Grimminger, Peter P

AU - Hölscher, Arnulf H

AU - Semrau, Robert

AU - Arnold, Dirk

AU - Dellas, Kathrin

AU - Debucquoy, Annelies

AU - Haustermans, Karin

AU - Machiels, Jean-Pascal H

AU - Sempoux, Christine

AU - Rödel, Claus

AU - Bracko, Matej

AU - Velenik, Vaneja

AU - Lenz, Heinz-Josef

PY - 2011

Y1 - 2011

N2 - Cetuximab has shown significant clinical activity in metastatic colon cancer. However, cetuximab-containing neoadjuvant chemoradiation has not been shown to improve tumor response in locally advanced rectal cancer patients in recent phase I/II trials. We evaluated functional germline polymorphisms of genes involved in epidermal growth factor receptor pathway, angiogenesis, antibody-dependent cell-mediated cytotoxicity, DNA repair, and drug metabolism, for their potential role as molecular predictors for clinical outcome in locally advanced rectal cancer patients treated with preoperative cetuximab-based chemoradiation.

AB - Cetuximab has shown significant clinical activity in metastatic colon cancer. However, cetuximab-containing neoadjuvant chemoradiation has not been shown to improve tumor response in locally advanced rectal cancer patients in recent phase I/II trials. We evaluated functional germline polymorphisms of genes involved in epidermal growth factor receptor pathway, angiogenesis, antibody-dependent cell-mediated cytotoxicity, DNA repair, and drug metabolism, for their potential role as molecular predictors for clinical outcome in locally advanced rectal cancer patients treated with preoperative cetuximab-based chemoradiation.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Combined Modality Therapy

KW - Mutation

KW - Neoadjuvant Therapy

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Proto-Oncogene Proteins/genetics

KW - ras Proteins/genetics

KW - Antibodies, Monoclonal/administration & dosage

KW - Epidermal Growth Factor/genetics

KW - Polymorphism, Genetic

KW - Rectal Neoplasms/drug therapy/genetics/radiotherapy

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Combined Modality Therapy

KW - Mutation

KW - Neoadjuvant Therapy

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Proto-Oncogene Proteins/genetics

KW - ras Proteins/genetics

KW - Antibodies, Monoclonal/administration & dosage

KW - Epidermal Growth Factor/genetics

KW - Polymorphism, Genetic

KW - Rectal Neoplasms/drug therapy/genetics/radiotherapy

M3 - SCORING: Journal article

VL - 17

SP - 5161

EP - 5169

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 15

M1 - 15

ER -